- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07470320
Biología de la Placenta en la Salud y la Enfermedad
Biología Placentaria en la Salud y la Enfermedad
Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.
A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.
This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.
Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Professor Manu Vatish
- Número de teléfono: +441865 221009
- Correo electrónico: manu.vatish@wrh.ox.ac.uk
Ubicaciones de estudio
-
-
-
Oxford, Reino Unido
- Reclutamiento
- Oxford University Hospitals NHS Foundation Trust
-
Contacto:
- Clinical Research Group
- Número de teléfono: +441865 221107
- Correo electrónico: clinicalresearchgroup@wrh.ox.ac.uk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.
Participants will include:
- Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
- Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
- Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
- Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.
Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.
Descripción
Inclusion Criteria:
-
Female, aged 18 years or above
-
Willing and able to give informed consent for participation in the study
-
Able to read and understand written and spoken English to comprehend study materials and give informed consent
-
Non-pregnant women in good general health OR pregnant women who fall into one of the following:
- Healthy pregnancy
- Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
- Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
- Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
- Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies
Exclusion Criteria:
- Non-pregnant participants with active health conditions that could confound study outcomes
- Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: OTHER
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Mujeres embarazadas diagnosticadas con preeclampsia
|
There are no interventions for this study |
|
Mujeres embarazadas diagnosticadas con diabetes mellitus gestacional
|
There are no interventions for this study |
|
Mujeres embarazadas diagnosticadas con restricción del crecimiento fetal
|
There are no interventions for this study |
|
Mujeres embarazadas sanas
|
There are no interventions for this study |
|
Mujeres sanas no embarazadas
|
There are no interventions for this study |
|
Mujeres embarazadas predispuestas a preeclampsia
|
There are no interventions for this study |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
Periodo de tiempo: Baseline and at delivery
|
Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles |
Baseline and at delivery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Quantitative and qualitative differences in inflammatory immune cells
Periodo de tiempo: baseline and delivery
|
Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured |
baseline and delivery
|
|
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
Periodo de tiempo: Baseline and delivery
|
Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions |
Baseline and delivery
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades del sistema endocrino
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades metabólicas
- Complicaciones del embarazo
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Enfermedades Fetales
- Trastornos del crecimiento
- Hipertensión
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Diabetes Gestacional
- Preeclampsia
- Retraso del crecimiento fetal
- Hipertensión, inducida por el embarazo
Otros números de identificación del estudio
- 18939
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .